AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02476760 — intervention group
Intervention type: DRUG
Intervention: DPP-4 inhibitors
Description: Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study NCT02476760 — intervention group
Intervention type: DRUG
Intervention: GLP-1 analogs
Description: Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
Study NCT00547300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol ER
Description: Metoprolol ER once daily, oral administration
Study NCT00547300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol once daily, oral administration
Study NCT04532697 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
Study NCT00010218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: karenitecin
Study NCT02476760 — intervention group
Intervention type: DRUG
Intervention: Insulins
Description: Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
Study NCT02476760 — intervention group
Intervention type: DRUG
Intervention: Biguanides
Description: Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study NCT02840812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: Nemonoxacin Malate Capsules 500mg single dose oral
Study NCT04833829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHIMES Intervention
Description: There are six components to the intervention:~1. Posters and other print materials to prompt providers and patients to discuss MH care engagement.~2. Brief verbal scripts to help HIV providers facilitate patient MH engagement and discuss barriers to MH utilization.~3. Expanded MH screening procedures, including at initial intake.~4. Case management, emphasizing MH care engagement.~5. Interactive trainings for all HIV providers on MH needs, screening/treatment, and barriers to MH service utilization specific to YB-GBMSM.~6. Regular case review meetings.
Study NCT04833829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The standard of care practices of referring patients to mental health services of the clinic during Months 1 - 12 of the study.
Study NCT02476760 — intervention group
Intervention type: DRUG
Intervention: Sulfonylureas
Description: Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study NCT04410692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prediction Market
Description: Participants bet on likely future outcomes using a prediction market
Study NCT03455075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethandrolone-Undecanoate
Description: Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.
Study NCT03455075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 0.03 MG
Description: Single doses of LNG administered in 30 mcg capsules.
Study NCT02476760 — intervention group
Intervention type: DRUG
Intervention: Thiazolidinediones
Description: Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study NCT02476760 — intervention group
Intervention type: DRUG
Intervention: Alpha-glucosidase inhibitors
Description: Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study NCT03455075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
Study NCT02476760 — intervention group
Intervention type: DRUG
Intervention: Meglitinides
Description: Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
Study NCT03820999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral and written information on tick-bites and Lyme disease
Description: See under study arm descriptions
Study NCT00390949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer education among commercial sex workers and clients
Study NCT00390949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condom distribution and promotion
Study NCT00390949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Syndromic treatment of sexually transmitted infections
Study NCT00390949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic counselling for STI patients
Study NCT03076528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensor-based interactive exercise (game-based exercise)
Description: This intervention includes interactive game-based lower extremity training including repetitive ankle movements in multiple directions. Wearable sensors will provide real-time feedback from foot and ankle position and allow perception of motor-errors during each motor-action
Study NCT03076528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-technology foot and ankle exercise program
Description: Subjects are asked to perform non-technology based foot and ankle exercises, which include plantar flexion and extension.
Study NCT02585973 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AZD1775
Description: AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.
Study NCT02585973 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: 40 mg/m2 IV infused over 1 hour D1 of each week of radiation
Study NCT02585973 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity Modulated Radiotherapy Treatments
Description: Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks
Study NCT03628001 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ERCP
Description: Pts will be randomized with or without sphinterectomy.
Study NCT01483612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary lifestyle intervention
Description: Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting.~The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity.
Study NCT03455075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
Study NCT04793932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAXG
Description: Nab-paclitaxel, cisplatin and gemcitabine drugs will be administered on day 1 and 15 every 28 days. Capecitabine tablets will be taken orally on days 1 to 28, every 28 days
Study NCT04793932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFIRINOX
Description: Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days
Study NCT04793932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: short-course chemotherapy
Description: other two months of chemotherapy after surgery
Study NCT04793932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long-course chemotherapy
Description: other two months of chemotherapy before surgery
Study NCT02963909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IXIARO
Description: An inactivated vaccine indicated for active immunization for the prevention of disease caused by Japanese encephalitis virus (JEV).
Study NCT02963909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride 5 mcg
Study NCT02963909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YF Vax 17D Strain
Description: A stabilised Yellow Fever Vaccine (Live) that is an injectable suspension of the attenuated 17D strain of yellow fever virus. The vaccine is injected by the subcutaneous route.
Study NCT02963909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Description: Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
Study NCT04404816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heliox
Description: NIV-NAVA with a conventional gas mixture (air-oxygen) at baseline, 3 hours of NIV-NAVA with heliox and return to NIV-NAVA with air-oxygen.
Study NCT02028156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partially Hydrolyzed Infant Formula
Description: Commercially available infant formula
Study NCT01542684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: Starting dose: 40 mg/m\^2 intravenously (IV) or subcutaneously (SQ) daily for 4 days.
Study NCT01542684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg/m\^2 IV or SQ one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
Study NCT00101894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX-4
Description: The FOLFOX-4 regimen will be administered every 2 weeks as follows:~Day 1: oxaliplatin (ELOXATIN™) 85 mg/m2 IV infusion and leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion given over 120 ± 10 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed by 5-FU 600 mg/m2 IV infusion as a 22-hour ± 2 hours continuous infusion Day 2: leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion over 120 ± 10 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed
Study NCT00101894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 is a small organic molecule that has been shown in preclinical pharmacology studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively inhibiting all known VEGF receptors, PDGF receptor, and Kit.
Study NCT00101894 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab (Part 1a only)
Description: Panitumumab will be administered by IV infusion at a dose of 6 mg/kg on day 1 of each 2-week cycle.
Study NCT00101894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan will be administered over 90 minutes ± 15 minutes on day 1 of each 2-week cycle. Leucovorin will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing, immediately followed by a 5-FU bolus and a 5-FU 46-hour ± 2-hour continuous intravenous infusion.
Study NCT03978897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction tourniquet
Description: A blood flow restriction tourniquet, which impedes arterial flow to extremity at 50% of usual flow.
Study NCT03978897 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evidence based physical/occupational therapy
Description: Up to date physical/occupational therapy for lateral epicondylitis
Study NCT02998515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Companion (Liquid oxygen device)
Study NCT02998515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activox (concentrator)
Study NCT06566105 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: precision medicine approach
Description: precision medicine approach to improvement of risk stratification of hepatic and cardiovascular complications in non-alcoholic fatty liver disease in a group of healthy subjects at increased risk of metabolic pathologies
Study NCT03358732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endometrial navigation one day before the embyo transfer using IUI catheter ,
Description: one day before the actual ET, the participants, in the study group, were taken into the operating room with a moderately full bladder at 10 am. The patient was placed in the lithotomy position and a sterile speculum was inserted into the vagina. The cervix was cleaned with sterile swabs and sterile water, and a mock transfer was performed using a soft catheter (Wallace Intrauterine Insemination Catheter; Sims Portex Ltd., Hythe, Kent, UK). The catheter has an outer sheet with memory , to aid insertion, and a soft inner catheter with atraumatic tip. Under ultrasound guidance, only the soft inner catheter was introduced beyond the internal cervical os till it was 0.5 cm from the fundus. It was, then, gently withdrawn out of the uterus, and the speculum was removed.
Study NCT01106352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.
Study NCT01106352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (75 mg/m\^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m\^2 is allowed as per the approved docetaxel label.
Study NCT01106352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (75 mg/m\^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m\^2 is allowed as per the approved docetaxel label.
Study NCT01315054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMT provider dosage training
Description: Training on methadone dosing provided to health care providers working in methadone maintenance clinics
Study NCT01315054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: targeted counseling
Description: targeted counseling provided to methadone maintenance clinic attendees
Study NCT01315054 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: national guidelines
Description: Provided a hard copy of the existing national guidelines for methadone dosing
Study NCT01315054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: national guidelines
Description: Provided a hard copy of the existing national guidelines for methadone dosing
Study NCT01890109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered via subcutaneous injection.
Study NCT01890109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via subcutaneous injection
Study NCT00354731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Description: Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M
Study NCT00354731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
Study NCT00354731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
Study NCT00187057 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vinblastine, vincristine, prednisone, daunorubicin
Description: See Detailed Description section for details of treatment interventions.
Study NCT00187057 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
Description: See Detailed Description section for details of treatment interventions.
Study NCT00187057 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: etoposide, cytarabine, mercaptopurine
Description: See Detailed Description section for details of treatment interventions.
Study NCT00187057 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone, procarbazine
Description: See Detailed Description section for details of treatment interventions.
Study NCT00187057 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: chemotherapy, intrathecal chemotherapy, steroid therapy
Description: See Detailed Description section for details of treatment interventions.
Study NCT02026102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICD Decision Aid Toolkit
Description: Research assistants will provide patients with a toolkit of decision aids. Participants will have the option of using all of the decision aids or just some of the decision aids.
Study NCT01403428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation
Description: Noninvasive positive pressure ventilation (NPPV) will deliver pressurized gas through a nasal or oronasal mask, connected to a pressure targeted ventilator. NPPV provides ventilator support without the use of an endotracheal tube. Standard of care includes use of corticosteroids, oxygen, short acting β-agonist and inhaled ipratropium bromide.
Study NCT01286207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg
Description: Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
Study NCT01286207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Description: Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
Study NCT01286207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Active standard care
Study NCT01307631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT01307631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03563235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xulin Jiangu granules
Description: Xulin Jiangu granules tablets
Study NCT03563235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xulin Jiangu granules
Description: Xulin Jiangu granules tablets
Study NCT03563235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol capsules
Description: Calcitriol capsules tablets
Study NCT03563235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol capsules
Description: Calcitriol capsules tablets
Study NCT02139579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg every 3 weeks
Study NCT01333631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer
Study NCT01855100 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
Study NCT02179931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flupentixol/melitracen film-coated tablet
Study NCT02179931 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Flupentixol/melitracen coated tablet (Deanxit®)
Study NCT01174368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cancer Macrobead placement in abdominal cavity
Description: 8 macrobeads per kilogram
Study NCT02076230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] TH-302 (Label 1)
Description: \[14C\]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
Study NCT02076230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] TH-302 (Label 2)
Description: \[14C\]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
Study NCT02076230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unlabeled TH-302
Description: Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m\^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.
Study NCT01839565 — intervention group
Intervention type: DEVICE
Intervention: Quadrilateral Surface Plate
Description: Patients with acetabular fracture surgically treated using the Quadrilateral Surface Plate